The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued ...

Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released ...

Inhibikase's neurodegenerative disease portfolio is led by risvodetinib, a selective c-Abl inhibitor to treat Parkinson’s and Parkinson ... Phase 2b ‘702’ trial to evaluate IkT-001Pro as a treatment ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

A research team reported recently that heart muscle cells grown from induced pluripotent stem cells can integrate into the hearts of monkeys with a state of pressure overload.

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.